Integrated ADME Evaluation Of 14C-Nolasiban

An advertisement features three scientific posters by ObsEva on CYP phenotyping, Radiolabelled ADME studies, and comparative metabolism of 14C-Nolasiban. There is a "Download Posters Below" button. The image includes Pharmaron and ObsEva logos.

Poster Authors:

Eleanor Barton¹, Caroline Clegg¹, Ray Cooke¹, Rakhsar Shabir¹, Claire Henson¹, Richard Cole¹, Michael Hall¹, Jessica Richardson¹, Rakhsar Shabir¹, Rebecca Shellard¹, Dylan Williams¹, Jean-Pierre Gotteland², Oliver Pohl², Line Marchand²,

¹Pharmaron UK Ltd, Rushden, UK

²ObsEva SA, Geneva, Switzerland

Pharmaron presented a number of posters at the recent ISSX conference showcasing its experience within radiolabelled ADME non-clinical and clinical studies. This last set of posters focuses on the work conducted for ObsEva (Switzerland) on one of their lead candidates, Nolasiban, being developed to increase the chances of successful pregnancies among patients following Assisted Reproductive Technology (ART).

The posters show that the use of ¹⁴C radiolabel across in vitro, non-clinical and clinical ADME can lead to a more comprehensive elucidation of the human metabolism, the underlying biotransformation pathways and ultimately the determination of the safety of the drug and its metabolites.

Capabilities

Knowledge Center

Connect with a Scientific Expert

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.